Case Reports
Early Access
Papillon-Lefèvre syndrome with excellent response to risankizumab
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 25 February 2026
141
Views
138
Downloads
Authors
Papillon-Lefèvre syndrome (PLS) is a rare autosomal recessive genodermatosis. It is clinically characterized by diffuse palmoplantar keratoderma (PPK), psoriasiform skin lesions, and rapidly progressive periodontopathy. Management of PLS can be challenging. Herein, we present the case of a 27-year-old female who experienced poor response to multiple therapies, including topical keratolytic creams, oral isotretinoin and acitretin, and the tumor necrosis factor (TNF) inhibitor adalimumab. Notably, she achieved complete resolution of her cutaneous manifestations following treatment with the interleukin (IL)-23 inhibitor risankizumab.
Downloads
Download data is not yet available.
Citations
1. Wani AA, Devkar N, Patole MS, Shouche YS. Description of two new cathepsin C gene mutations in patients with Papillon-Lefèvre syndrome. J Periodontol 2006;77:233-7.
2. James WD, Berger T, Elston D. Andrews’ Diseases of the Skin: Clinical Dermatology. 10th ed. Philadelphia: Saunders; 2006.
3. Al-Khenaizan S. Papillon-Lefévre syndrome: the response to acitretin. Int J Dermatol 2002;41:938-41.
4. Drucker DB, Marshall R, Bird PS. Aetiology of Papillon LeFèvre syndrome. Anaerobe 2001;7:151-8.
5. Cagli NA, Hakki SS, Dursun R, et al. Clinical, genetic, and biochemical findings in two siblings with Papillon-Lefèvre syndrome. J Periodontol 2005;76:2322-9.
6. Sreeramulu B, Shyam ND, Ajay P, Suman P. Papillon-Lefèvre syndrome: clinical presentation and management options. Clin Cosmet Investig Dent 2015;7:75-81.
7. Potestio L, Martora F, Lauletta G, et al. The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials. Clin Cosmet Investig Dermatol 2024;17:829-42.
8. Almukhadeb E, Alanazi W, Alshareef R, et al. Excellent response to adalimumab in a patient with Papillon–Lefèvre syndrome: a case report. JEADV Clin Pract 2023;2:621-4.
9. Latour-Álvarez I, Ortega-Ramírez J, Alonso-Serrano E, Torrelo A. Novel compound heterozygous mutation in CTSC gene with response to ustekinumab. J Eur Acad Dermatol Venereol 2023;37:e798-800.
10. Yoshida I, Lommel K, Oji V, et al. Use of Retinoids and Secukinumab in a Patient with Papillon-Lefèvre Syndrome. J Investig Dermatol 2024;144:S272.
11. Li J, Wang Z, Xu Z. Secukinumab and Upadacitinib Treatment for Papillon-Lefèvre Syndrome in 2 Cases. JAMA Dermatol 2025;161:887-90.
How to Cite
1.
Alibrahim L, Alrashid S, Aleissa M. Papillon-Lefèvre syndrome with excellent response to risankizumab. Dermatol Reports [Internet]. 2026 Feb. 25 [cited 2026 Apr. 18];. Available from: https://journals.pagepress.net/dr/article/view/10309
Copyright (c) 2026 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
